PIK3CA and cancer: Since MAPK (RAS-RAF-MEK-ERK) pathway deregulation was identified as a dominant determinant in cancer resistance to PI3K inhibitors [37], concurrent targeting of both pathways can be hypothesized to improve the efficacy of treatment and provide better clinical outcome [38].